Under the Affordable Care Act, most health insurance policies must cover prescription drugs.
Allegan-based Perrigo Co. (NYSE:PRGO) and Ireland’s Elan Corp. plc (NYSE:ELN) Friday announced that the Irish High Court has approved Perrigo’s pending acquisition of Elan.
The Allegan generic drugmaker and store brand health products producer Perrigo Co. (NYSE: PRGO) Wednesday announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% and has notified Dow Pharmasciences, the owner of the New Drug Application, of its filing.
The generic prescription drug and store-brand health products maker Perrigo Co. (NYSE: PRGO) announced that its shareholders approved proposals related to its acuqisition of Ireland’s Elan Corp. plc at a special meeting Monday.
Perrigo Co. (NYSE: PRGO) announced that it has received final approval for its abbreviated new drug application for nitroglycerin lingual spray, 400 mcg/spray, the generic equivalent to Nitrolingual Pumpspray.
The Allegan health and beauty products maker Perrigo Co. (Nasdaq: PRGO) reported record sales and net income for the fourth fiscal quarter and fiscal year ended June 29.
Perrigo Co. (NYSE: PRGO) announced that its board of directors declared a quarterly dividend of 9 cents per share.
The Allegan generic drug maker will begin making two oils for dermatitis and a cancer drug.
The Allegan generic and store-brand health products maker Perrigo Co. announced early Monday that it would acquire Dublin, Ireland-based Elan Corp. plc for $8.6 billion (5.6 billion pounds).
The generic drug and store brand health products maker Perrigo Co. (Nasdaq: PRGO) Wednesday reported record revenue of $919.8 million in the third fiscal quarer ended March 30, up from $778 million a year earlier.